UroGen: Expect Rough Patch Before Strong Recovery In 2026

UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.
MedPage Today on MSN

Medicare Finalizes Physician Fee Schedule for 2026

The Centers for Medicare & Medicaid Services (CMS) on Friday finalized its annual physician fee schedule for 2026, giving ...
Becker's ASC

USPI wins big with high-acuity procedures

Investment in high-acuity procedures is one of the “biggest drivers” of ASC volume growth for Dallas-based United Surgical Partners International, CEO Saum Sutaria, MD, said during an earnings call ...
Becker's ASC

From independence to integration: Why interoperability matters to every ASC

In my conversations with ASC leaders this year, one theme has been impossible to miss: Change is everywhere. Centers are expanding, merging, modernizing, and rethinking how they use technology to ...
Nasdaq

First Trust Senior Floating Rate Income Fund II Common Shares of Beneficial Interest (FCT)

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...
Everyday Health

Why More Couples Are Divorcing at Older Ages (and After More Years of Marriage) Than Before — and What You Can Do to Avoid It

Baby boomers have gotten credit for all kinds of societal trends, from the counterculture to consumerism. Now they’re behind what’s known as “gray divorce” — couples calling it quits in middle age or ...